AMRINONE - Watsons Health

AMRINONE

Heart failure

 

DOSAGE

  • Adult
    • IV Loading dose: 750 mcg/kg via slow injection; Dose may be repeated 30 mins later if necessary
    • Maintenance: 5-10 mcg/kg/min via infusion. Max dose: 10 mg/kg in 24 hr.

 

CONTRAINDICATIONS

  • Hypersensitivity
  • Incompatible with glucose-containing solutions and furosemide.
  • Obstructive pulmonary or aortic disease, hypertrophic cardiomyopathy
  • During administration of the drug BP and heart rate must be monitored
  • Maintenance of fluid and electrolytes
  • Monitoring of platelet count and liver function must be done
  • If you are planning to be pregnant or think you may be pregnant, discuss the risks and benefits of use with your doctor. Before breast-feeding, consult your physician.
  • Minor side effects (if these symptoms persist or worsen, inform your doctor)
    • GI disturbances, nausea, vomiting, thrombocytopenia, hypotension, chest pain, hypersensitivity, myositis, vasculitis, nail discoloration, Injection site pain, decreased tear production
  • Serious side effects (inform your doctor immediately)
    • Cardiac arrhythmia, hepatotoxicity.
  • If overdose is suspected, contact a poison control center or emergency room immediately.
    • Severe hypotension

 

DRUG INTERACTIONS

Taking multiple drugs may affect how medications work and/or cause unwanted side effects. List down all the medications you are taking and inform your physician and pharmacist. Do not take, discontinue, or alter any dose of medications without prior approval of your physician.

 

  • Products that may interact with this medication include:
    • Amrinone and dextrose or furosemide

Related Articles

DTP-HIB Vaccine

DTP-HIB vaccine is a combined vaccine of adsorbed diphtheria, tetanus toxoid and acellular pertussis and of Haemophilus influenzae type b conjugate vaccines. It is a [...]

Tenecteplase

Tenecteplase is a tissue-type plasminogen activator (tPA), a biosynthetic form of human enzyme that is a fibrin-specific thrombolytic agent, converting plasminogen to [...]

Selexipag

Selexipag is a selective non-prostanoid agonist of prostacyclin (IP) receptor, that stimulates the release of prostacyclin, which is responsible to induce [...]